2 research outputs found
Relationship Between Preexisting Cardiovascular Disease and Death and Cardiovascular Outcomes in Critically Ill Patients With COVID-19
BACKGROUND: Preexisting cardiovascular disease (CVD) is perceived as a risk factor for poor outcomes in patients with COVID-19. We sought to determine whether CVD is associated with in-hospital death and cardiovascular events in critically ill patients with COVID-19.
METHODS: This study used data from a multicenter cohort of adults with laboratory-confirmed COVID-19 admitted to intensive care units at 68 centers across the United States from March 1 to July 1, 2020. The primary exposure was CVD, defined as preexisting coronary artery disease, congestive heart failure, or atrial fibrillation/flutter. Myocardial injury on intensive care unit admission defined as a troponin I or T level above the 99th percentile upper reference limit of normal was a secondary exposure. The primary outcome was 28-day in-hospital mortality. Secondary outcomes included cardiovascular events (cardiac arrest, new-onset arrhythmias, new-onset heart failure, myocarditis, pericarditis, or stroke) within 14 days.
RESULTS: Among 5133 patients (3231 male [62.9%]; mean age 61 years [SD, 15]), 1174 (22.9%) had preexisting CVD. A total of 1178 (34.6%) died, and 920 (17.9%) had a cardiovascular event. After adjusting for age, sex, race, body mass index, history of smoking, and comorbidities, preexisting CVD was associated with a 1.15 (95% CI, 0.98-1.34) higher odds of death. No independent association was observed between preexisting CVD and cardiovascular events. Myocardial injury on intensive care unit admission was associated with higher odds of death (adjusted odds ratio, 1.93 [95% CI, 1.61-2.31]) and cardiovascular events (adjusted odds ratio, 1.82 [95% CI, 1.47-2.24]), regardless of the presence of CVD.
CONCLUSIONS: CVD risk factors, rather than CVD itself, were the major contributors to outcomes in critically ill patients with COVID-19. The occurrence of myocardial injury, regardless of CVD, and its association with outcomes suggests it is likely due to multiorgan injury related to acute inflammation rather than exacerbation of preexisting CVD.
REGISTRATION: NCT04343898; https://clinicaltrials.gov/ct2/show/NCT04343898
AngiotensinâConverting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVIDâ19
Background Use of angiotensinâconverting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) is thought to affect COVIDâ19 through modulating levels of angiotensinâconverting enzyme 2, the cell entry receptor for SARSâCoV2. We sought to assess the association between ACEi/ARB, biomarkers of inflammation, and outcomes in patients hospitalized for COVIDâ19. Methods and Results We leveraged the ISIC (International Study of Inflammation in COVIDâ19), identified patients admitted for symptomatic COVIDâ19 between February 1, 2020 and June 1, 2021 for COVIDâ19, and examined the association between inâhospital ACEi/ARB use and allâcause death, need for ventilation, and need for dialysis. We estimated the causal effect of ACEi/ARB on the composite outcomes using marginal structural models accounting for serial blood pressure and serum creatinine measures. Of 2044 patients in ISIC, 1686 patients met inclusion criteria, of whom 398 (23.6%) patients who were previously on ACEi/ARB received at least 1 dose during their hospitalization for COVIDâ19. There were 215 deaths, 407 patients requiring mechanical ventilation, and 124 patients who required dialysis during their hospitalization. Prior ACEi/ARB use was associated with lower levels of soluble urokinase plasminogen activator receptor and Câreactive protein. In multivariable analysis, inâhospital ACEi/ARB use was associated with a lower risk of the composite outcome of inâhospital death, mechanical ventilation, or dialysis (adjusted hazard ratio 0.49, 95% CI [0.36â0.65]). Conclusions In patients hospitalized for COVIDâ19, ACEi/ARB use was associated with lower levels of inflammation and lower risk of inâhospital outcomes. Clinical trials will define the role of ACEi/ARB in the treatment of COVIDâ19. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04818866